Previous close | 0.0850 |
Open | 0.0850 |
Bid | 0.0850 x 0 |
Ask | 0.1000 x 0 |
Day's range | 0.0850 - 0.0850 |
52-week range | 0.0840 - 0.5300 |
Volume | |
Avg. volume | 300 |
Market cap | 4.365M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 28 May 2024 - 03 Jun 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
OXFORD, England, October 18, 2023--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform and Bupa, the UK’s leading health insurer, announce a strategic agreement to give Bupa patients access to OBD’s EpiSwitch CiRT (Checkpoint inhibitor Response Test).
OXFORD, England, October 03, 2023--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform, confirms the assignment and publication of a Proprietary Laboratory Analysis Code (PLA Code) by the American Medical Association’s CPT (Current Procedural Terminology) Editorial Board (https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes).